ATE305810T1 - Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält - Google Patents

Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält

Info

Publication number
ATE305810T1
ATE305810T1 AT00110811T AT00110811T ATE305810T1 AT E305810 T1 ATE305810 T1 AT E305810T1 AT 00110811 T AT00110811 T AT 00110811T AT 00110811 T AT00110811 T AT 00110811T AT E305810 T1 ATE305810 T1 AT E305810T1
Authority
AT
Austria
Prior art keywords
dha
epa
acid
omega
pharmaceutical composition
Prior art date
Application number
AT00110811T
Other languages
English (en)
Inventor
Hajime Shibuya
Original Assignee
Pro Aparts Investimentos E Con
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE305810(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pro Aparts Investimentos E Con filed Critical Pro Aparts Investimentos E Con
Application granted granted Critical
Publication of ATE305810T1 publication Critical patent/ATE305810T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00110811T 2000-05-22 2000-05-22 Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält ATE305810T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110811A EP1157692B1 (de) 2000-05-22 2000-05-22 Fettsäure enthaltende pharmazeutische Zusammensetzung die wenigstens 80 Gew. % EPA und DHA enthält

Publications (1)

Publication Number Publication Date
ATE305810T1 true ATE305810T1 (de) 2005-10-15

Family

ID=8168789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00110811T ATE305810T1 (de) 2000-05-22 2000-05-22 Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält

Country Status (6)

Country Link
EP (1) EP1157692B1 (de)
AT (1) ATE305810T1 (de)
DE (1) DE60022987T2 (de)
DK (1) DK1157692T3 (de)
ES (1) ES2246769T3 (de)
PL (1) PL347655A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US8114906B2 (en) * 2004-04-16 2012-02-14 Abbott Products Gmbh Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
KR20070038553A (ko) * 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
FR2878747B1 (fr) * 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1968567B1 (de) * 2005-12-20 2014-06-18 Cenestra, Llc Omega-3-fettsäure-formulierungen
EP2081550B2 (de) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Beschichtung von kapseln mit pharmazeutischen wirkstoffen
JP5591469B2 (ja) 2006-05-31 2014-09-17 持田製薬株式会社 多重リスク患者の心血管イベント発症予防用組成物
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
CN102552213A (zh) * 2007-06-29 2012-07-11 武田药品工业株式会社 无缝胶囊
US20090182049A1 (en) * 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
EP3187182B1 (de) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
RU2505292C2 (ru) 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
CN102421422A (zh) 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US20110082205A1 (en) * 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
ES2895477T3 (es) * 2009-10-23 2022-02-21 Basf As Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos
AU2013204090B2 (en) * 2009-12-30 2015-01-29 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
US9321715B2 (en) * 2009-12-30 2016-04-26 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
JP2013537186A (ja) * 2010-09-08 2013-09-30 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物
KR20130139896A (ko) * 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
EP2800469B1 (de) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP2881456A1 (de) 2013-12-04 2015-06-10 Natac Pharma, S.L. Enzymatisches Verfahren zur Trennung von Phytansäure aus Fetten oder Ölen damit und zur Wiederherstellung unveränderter, phytansäurefreier Produkte
EP2883860B1 (de) 2013-12-11 2016-08-24 Novasep Process Chromatografisches Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren
JP6303017B2 (ja) 2014-01-07 2018-03-28 ノヴァセプ プロセスNovasep Process 芳香族アミノ酸を精製する方法
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10821090B2 (en) 2015-03-26 2020-11-03 Tiberio Bruzzese Purified compositions of polyunsaturated fatty acids, their preparation method and their use
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Also Published As

Publication number Publication date
DE60022987T2 (de) 2006-10-19
ES2246769T3 (es) 2006-03-01
PL347655A1 (en) 2001-12-03
EP1157692B1 (de) 2005-10-05
EP1157692A1 (de) 2001-11-28
DK1157692T3 (da) 2006-02-06
DE60022987D1 (de) 2005-11-10

Similar Documents

Publication Publication Date Title
DE60022987D1 (de) Fettsäure enthaltende pharmazeutische Zusammensetzung die wenigstens 80 Gew. % EPA und DHA enthält
NO20004615L (no) FremgangsmÕte for fremstilling av linolsyre, og preparater inneholdende denne
KR0126286B1 (ko) 지방산 조성물
JP2657056B2 (ja) γ‐リノレン酸の豊富化方法
BR0112680A (pt) Genes elongase e usos dos mesmos
JPH0232017A (ja) 精神分裂症および/または関連した晩発性運動障害の治療のための薬剤を製造する方法
CY1105119T1 (el) Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων
RU2002133098A (ru) Терапевтические комбинации жирных кислот
WO2000012720A8 (en) Elongase genes and uses thereof
BR9406940A (pt) Magnésio-omeprazol processo para a preparação de magnésio-omeprazol composição farmacêutica formulação farmacêutica para a administração oral forumulação de tablete uso do magnesio-omeprazol processo para a inibição da secreção de ácido gástrico em mamiferos e no homem e processo para o tratamento das doenças relacionadas com o ácido gastrico em mamiferos e no homem
CA2362271A1 (en) Essential fatty acids in the prevention of cardiovascular events
JPS61215322A (ja) γ‐リノレン酸またはジホモ‐γ‐リノレン酸の使用方法
JPH0779662B2 (ja) 食品組成物
WO2007017240A3 (en) Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids
EP1801226A3 (de) Arachidonsäure und Verfahren zu ihrer Herstellung und Verwendung
DE69523654T2 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
ES2188433T1 (es) Procedimiento para la preparacion de sales calcicas de acidos grasos para gliceridos elevados en contenidos de aceites.
ATE258792T1 (de) Diät mit hohem lipidgehalt
JPH01139529A (ja) 歯周病治療剤及び歯周病治療用組成物
KR20150131302A (ko) 구강 건조증의 치료 및 치아 치료를 위한 조성물
EP0257081A1 (de) Verfahren zur änderung der lipidstruktur der zellmembranen und arzneimittel dazu
JPS58159418A (ja) 医薬組成物
KR910700248A (ko) 위산 분비 억제 효과를 갖는 화합물 및 그의 제조 방법
WO1996031457A1 (en) Triglycerides
ATE179889T1 (de) Arzneimittel, die ester omega-3 polyungesättigter säuren enthalten und deren verwendung in der topischen behandlung morbider erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1157692

Country of ref document: EP